Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.

New therapies for obesity

Open access
Papamargaritis, Dimitris, le Roux, Carel W, Holst, Jens J, Davies, Melanie J · 2024 · Cardiovascular Research

Abstract

Obesity is a chronic disease associated with serious complications and increased mortality. Weight loss (WL) through lifestyle changes results in modest WL long-term possibly due to compensatory biological adaptations (increased appetite and reduced energy expenditure) promoting weight gain. Bariatric surgery was until recently the only intervention that consistently resulted in ≥ 15% WL and maintenance. Our better understanding of the endocrine regulation of appetite has led to the development of new medications over the last decade for the treatment of obesity with main target the reduction of appetite. The efficacy of semaglutide 2.4 mg/week—the latest glucagon-like peptide-1 (GLP-1) receptor analogue—on WL for people with obesity suggests that we are entering a new era in obesity pharmacotherapy where ≥15% WL is feasible. Moreover, the WL achieved with the dual agonist tirzepatide (GLP-1/glucose-dependent insulinotropic polypeptide) for people with type 2 diabetes and most recently also obesity, indicate that combining the GLP-1 with other gut hormones may lead to additional WL compared with GLP-1 receptor analogues alone and in the future, multi-agonist molecules may offer the potential to bridge further the efficacy gap between bariatric surgery and the currently available pharmacotherapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cvr/cvac176

Cites

141 of 141 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The effect of different weight loss interventions [low-calorie diet, exercise, pharmacotherapy (GLP-1 receptor analogues), and bariatric surgery] on appetite.
Figure 1 The effect of different weight loss interventions [low-calorie diet, exercise, pharmacotherapy (GLP-1 receptor analogues), and bariatric surgery] on appetite.CC BY · PubMed Central
Figure 2 The efficacy gap in weight loss between lifestyle interventions, approved pharmacotherapies for obesity over last decade (plus tirzepatide) and bariatric surgery in adults without type 2 diabetes (Figure 2A) and in adults with type 2 diabetes (Figure 2B). Data in Figure 2A are based on published clinical trials used (A) lifestyle interventions (500 kcal deficit diet plus advise for physical activity or intensive behavioural therapy) plus placebo (green background), 15,62,65–68,70 (B) liraglutide 3 mg,68,70 naltrexone/buproprion 32/360,65–67 phentermine/topiramate 15/92,62 semaglutide 2.4 mg,15,74–76 and tirzepatide 5 and 15 mg77 plus lifestyle interventions (approved obesity pharmacotherapies plus tirzepatide, orange background) or c) sleeve gastrectomy112 and Roux-en-Y gastric bypass112 (bariatric surgery, blue background) in adults without type 2 diabetes. Data in Figure 2B are based on published clinical trials used a) lifestyle interventions (500 kcal deficit diet plus advise for physical activity or intensive behavioural therapy) plus placebo (green background),78–80,82 (B) liraglutide 3 mg,80,81 naltrexone/buproprion 32/360,79 phentermine/topiramate 15/92,78 semaglutide 2.4 mg82 plus lifestyle interventions, and tirzepatide 5 mg and 15mg84,85,87 (approved obesity pharmacotherapies plus tirzepatide, orange background) or c) sleeve gastrectomy113 and Roux-en-Y gastric bypass113 (bariatric surgery, blue background) in adults with type 2 diabetes.
Figure 2 The efficacy gap in weight loss between lifestyle interventions, approved pharmacotherapies for obesity over last decade (plus tirzepatide) and bariatric surgery in adults without type 2 diabetes (Figure 2A) and in adults with type 2 diabetes (Figure 2B). Data in Figure 2A are based on published clinical trials used (A) lifestyle interventions (500 kcal deficit diet plus advise for physical activity or intensive behavioural therapy) plus placebo (green background), 15,62,65–68,70 (B) liraglutide 3 mg,68,70 naltrexone/buproprion 32/360,65–67 phentermine/topiramate 15/92,62 semaglutide 2.4 mg,15,74–76 and tirzepatide 5 and 15 mg77 plus lifestyle interventions (approved obesity pharmacotherapies plus tirzepatide, orange background) or c) sleeve gastrectomy112 and Roux-en-Y gastric bypass112 (bariatric surgery, blue background) in adults without type 2 diabetes. Data in Figure 2B are based on published clinical trials used a) lifestyle interventions (500 kcal deficit diet plus advise for physical activity or intensive behavioural therapy) plus placebo (green background),78–80,82 (B) liraglutide 3 mg,80,81 naltrexone/buproprion 32/360,79 phentermine/topiramate 15/92,78 semaglutide 2.4 mg82 plus lifestyle interventions, and tirzepatide 5 mg and 15mg84,85,87 (approved obesity pharmacotherapies plus tirzepatide, orange background) or c) sleeve gastrectomy113 and Roux-en-Y gastric bypass113 (bariatric surgery, blue background) in adults with type 2 diabetes.CC BY · PubMed Central
Figure 3 Categorical weight loss (≥10% in Figure 3A, ≥ 15% in Figure 3B) in large clinical trials with the approved obesity pharmacotherapies over the last decade (plus tirzepatide) in people with and without type 2 diabetes (studies with follow-up 52–72 weeks).
Figure 3 Categorical weight loss (≥10% in Figure 3A, ≥ 15% in Figure 3B) in large clinical trials with the approved obesity pharmacotherapies over the last decade (plus tirzepatide) in people with and without type 2 diabetes (studies with follow-up 52–72 weeks).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 141 references

Research works printed but not linked: 2

  1. Aronne, 2021, Describing the weight-reduced state: physiology, Obesity (Silver Spring, 29, S9
  2. De Silva, 2011, The gut hormones PYY, Cell Metab, 14, 3

Cited by

See all 73

Metadata

Authors
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J.
Affiliations
  • University of Leicester (GB)
  • Diabetes Complications Research Centre, Conway Institute, University College Dublin , Dublin 4 , Ireland
  • University of Copenhagen (DK)
Corresponding author
Papamargaritis, Dimitris
Venue
Cardiovascular Research
Published
2022-11-30
Volume
119
Issue
18
Pages
2825-2842
ISSN
  • 0008-6363 (ISSN-L)
  • 1755-3245
OpenAlex
W4310416488
Cited by
73
References
141
Citations by year
2026: 12 · 2025: 19 · 2024: 31 · 2023: 11
FWCI
9.13
Type
journal article
Language
en
Open access
Locations
  • Cardiovascular Research (publishedVersion, public-domain)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • Ulster University Research Portal (Ulster University) (submittedVersion, public-domain)
  • Figshare (submittedVersion, cc-by)
Funders
  • Leicester NIHR Biomedical Research Centre
  • National Institute of Clinical Research Clinical Lectureship
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
obesity, obesity pharmacotherapy, weight loss, appetite regulation, bariatric surgery, semaglutide, GLP-1 receptor agonists, tirzepatide, glucose-dependent insulinotropic polypeptide, lifestyle intervention
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Appetite, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New therapies for obesity. https://app.cochat.ai/papers/10.1093/cvr/cvac176
The paper
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024). New therapies for obesity. Cardiovascular Research. https://doi.org/10.1093/cvr/cvac176

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.